Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: arnold silver who wrote (174)	1/7/2003 9:31:41 PM
From: JMarcus	Read Replies (2) \| Respond to of 3722

<<I can't even find a reason for the name change.>> The company is trying to distance itself from its SNAFU in trying to develop its once-flagship molecule, Neotrofin, for Alzheimers. News about that shady history isn't on SPPI's website, but you can find it on the old SI thread for NEOT. The announcement of Neotrofin's final demise is posted there: Message 17423517 The new focus of the company is cancer therapeutics. At least one biofreak thinks the new management may have a chance at turning the company around: siliconinvestor.com I lost a bundle on NEOT, so I'm gunshy, even though SPPI really is a completely new company. Marc

To: arnold silver who wrote (174)	1/8/2003 1:06:53 PM
From: Jibacoa	Respond to of 3722

In fact I can't even find a reason for the name change. I think the main reason was that Neotrofin was not as effective in trials against Alzheimer's as the company had hoped and R&D costs forced the firm to shift its focus from CNS diseases to cancer. Its present lead candidate drug (Satraplatin) is in Phase III for prostatic Ca and the company which originally mainly worked on drugs for CNS degenerative conditions now plans to license its CNS drug candidates to other developers. On Monday and yesterday there were some good upticks but today (with the help of the general market<g>) things are stalling at the 2.18 level. The shares need to close above its Dec. 12 H of $2.40 before it can test its November 7-November 8 double top at the $2.75 level The PSML data on SPPI at present:2.13 2.01 1.95 & 1.98 (The L average is still a little H for it to be on a frank UPTREND) But if sometime in the future it can close some of its late April down-gap it still would be a very good % gain from present levels.<g> bigcharts.marketwatch.com Bernard